Sanofi-Aventis - Biotech Market Share Report

Sanofi-Aventis market share report graphic featuring Sanofi and Lantus logosCompany: Sanofi-Aventis
2007 Sales: $3.2 billion
Market share: 4.3%
CAGR: 37.7%

What they have: Sanofi's top-selling biotech blockbuster is Lantus, a Type 1 and 2 diabetes treatment. The company also markets a host of vaccines through Sanofi Pasteur, the vaccine division of Sanofi-Aventis.

What to look for: Currently, only 10 percent of the drugs Sanofi makes are biologics; in an interview, Senior Vice President, Scientific and Medical Affairs Mark Cluzel said the company wants to boost that number to 20 or 30 percent by 2012. Sanofi is collaborating with Regeneron on its drug Aflibercept (VEGF Trap), a cancer drug in late-stage trials for prostate and lung cancer.

Sanofi-Aventis - Biotech Market Share Report
Read more on

Suggested Articles

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.

While screening Caenorhabditis elegans for genetic clues to the PI3K/Akt signaling pathway, scientists found a key protein for insulin synthesis.